openPR Logo
Press release

Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase) Pipeline Landscape and Therapeutic Assessment in H1 2017

07-05-2017 11:52 AM CET | Health & Medicine

Press release from: Pharmaceutical Research Reports [MRH]

Pharmaceutical Industry Research Reports - MRH

Pharmaceutical Industry Research Reports - MRH

According to the latest pipeline analysis, Aminopeptidase N (APN/CD13) acts as an exopeptidase and has been studied for decades. In recent years, it has been seen not only as a tumor-related target but also as a potential functional protein in various other physiological or pathological processes, such as analgesia, virus infection and inflammation. To elaborate further details on its global demand, a study titled “Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or EC 3.4.11.2) - Pipeline Review, H1 2017” has been recently broadcasted to the wide database of Market Research Hub (MRH). This report on the Aminopeptidase N market has been compiled by conducting both primary and secondary research and analyzes the market on the basis of its pipeline review.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157707

The study starts by presenting the comprehensive overview on Aminopeptidase N. his section highlights the development of therapeutics, pipeline products utilized in Aminopeptidase N, and a comparative analysis of these pipeline products. Aminopeptidase N (AP-N) or membrane alanyl aminopeptidase or alanyl aminopeptidase (AAP) is an enzyme encoded by the ANPEP gene. Aminopeptidase N or CD13 is a transmembrane protease present in a wide variety of human tissues and cell types including endothelial, epithelial, leukocyte and fibroblast. It is a multifunctional enzyme, related with tumorigenesis, immune system, pain etc. It has also analyzed that it plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. It also involved in the processing of various peptides including peptide hormones, such as angiotensin III and IV, neuropeptides and chemokines.

Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157707

In the next part of the report, the therapeutics still under development by both universities and companies have been presented. Moving further, the clinical late stage and early stage products have been analyzed in this study. The drug profiles, their mechanism of action, and their research and development progress have also been encapsulated in this study.

Moving further, the key dynamics impacting the development of the Aminopeptidase N targeted therapeutics development market has also been compiled in this study. At present, Aminopeptidase N has been associated with the growth of different human cancers and suggested as a suitable target for anti-cancerous therapy. Different approaches have been used to develop new drugs directed to this target, including enzyme inhibitors as well as APN-targeted carrier constructs. Also, it has a role in angiogenesis and promotes cholesterol crystallization.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/aminopeptidase-n-myeloid-plasma-membrane-glycoprotein-cd13-or-alanyl-aminopeptidase-or-aminopeptidase-m-or-microsomal-aminopeptidase-or-gp150-or-cd13-or-anpep-or-ec-34112-pipeline-review-h1-2017-report.html

Furthermore, the study also reviews key players involved in Aminopeptidase N targeted therapeutics development with their respective active and dormant projects. The vendor landscape section of the report throws light on the companies excelling in pipeline products in the market for Aminopeptidase N. Currently, MolMed SpA, Nippon Kayaku Co. Ltd. and Pharmaleads SA are the leading companies.

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read Industry News At: https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase) Pipeline Landscape and Therapeutic Assessment in H1 2017 here

News-ID: 609401 • Views: 290

More Releases from Pharmaceutical Research Reports [MRH]

Pipeline Analysis on Phenylalanine 4 Hydroxylase Reviewed by Company, Profiled D …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H1 2017”. This research study outlays comprehensive information on the Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration
Global Indoleamine 2, 3 Dioxygenase 1 Industry Vital Pipeline Review for the Fir …
The indoleamine 2, 3 Dioxygenase 1 or IDO1 market is developing since the cancer treatment sector relies heavily on its’ in-depth research and high-quality treatments. Looking into this huge potential, a new study has been added to the vast online repository of Market Research Hub (MRH), with the title ‘’Indoleamine 2, 3 Dioxygenase 1 (Indoleamine Pyrrole 2, 3 Dioxygenase 1 or IDO1 or EC 1.13.11.52) - Pipeline Review, H1 2017‘’.
Prosthetic Joint Infections - Clinical Trials Rise Due to Higher Disease Inciden …
Market Research HUB's Pharmaceutical and Healthcare latest pipeline guide Prosthetic joint infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prosthetic joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news
Hyperinsulinemia - Clinical Trials Rise Due to Higher Disease Incidences, H1 Rev …
Market Research HUB's Pharmaceutical and Healthcare latest pipeline guide Hyperinsulinemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperinsulinemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free

All 5 Releases


More Releases for Aminopeptidase

Renal Biomarker Market Analysis 2018 With Abbott, Alere Inc., Siemens Healthcare …
Renal Biomarker Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. The Renal Biomarker market report contains data for historic years 2015, the base year of calculation is 2016 and the Industry forecast period is 2017 to 2024. The Renal Biomarker Market report contains data for historic years 2015, the base
Aminopeptidase N: Clinical Trials Continue to Generate New Insights in Therapeut …
Advances in immunophenotyping diagnosis processes to garner information about leukemia or lymphoma and its plausible response to certain treatments has contributed towards clinical study and trials for aminopeptidase N (CD13). CD13 is extensively used as pan-myeloid marker to diagnose myeloid leukemia. In its recently added report titled, ‘Aminopeptidase N (Myeloid Plasma Membrane Glycoprotein CD13 or Alanyl Aminopeptidase or Aminopeptidase M or Microsomal Aminopeptidase or gp150 or CD13 or ANPEP or
Methionine Aminopeptidase 2 Global Key Players - Asieris Pharmaceuticals Co Ltd, …
Methionine Aminopeptidase 2 Overview Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18) - Methionine aminopeptidase 2 is an enzyme that in humans is encoded by the METAP2 gene. Methionine aminopeptidase 2 is a member of the dimetallohydrolase family is a cytosolic metalloenzyme that catalyzes the hydrolytic removal of N-terminal methionine residues from nascent proteins. Click here
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp16 …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Glutamyl Aminopeptidase Pipeline Review, H2 2017”, report provides Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The latest report Glutamyl Aminopeptidase - Pipeline Review, H2
Comprehensive Study on Methionine Aminopeptidase 2 (Initiation Factor 2 Associat …
According to a recent research study titled “Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)-Pipeline Review, H2 2017” which has been added to the comprehensive database of Market Research Hub (MRH), there are 13 molecules, of which 11 are developed by companies and remaining 2 are developed by universities. These 13 molecules are
Comprehensive Study on Methionine Aminopeptidase 2 (Initiation Factor 2 Associat …
According to a recent research study titled “Methionine Aminopeptidase 2 (Initiation Factor 2 Associated 67 kDa Glycoprotein or Peptidase M 2 or eIF 2 Associated p67 Homolog or METAP2 or EC 3.4.11.18)-Pipeline Review, H2 2017” which has been added to the comprehensive database of Market Research Hub (MRH), there are 13 molecules, of which 11 are developed by companies and remaining 2 are developed by universities. These 13 molecules are in